Genmab A/S (GMAB)
After hours:
| Previous close | 36.88 |
| Open | 37.10 |
| Bid | 37.22 x 800 |
| Ask | 37.62 x 800 |
| Day's range | 36.82 - 37.42 |
| 52-week range | 26.19 - 47.50 |
| Volume | |
| Avg. volume | 536,390 |
| Market cap | 24.643B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 56.51 |
| EPS (TTM) | 0.66 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.05 |
- GlobeNewswire
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; March 20, 2023 – Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 31, 2023 and comprises up to 220,000 shares. The following transactions were executed under the program from March 13, 2023, to March 17, 2023: No. of sharesAverage price (DKK)Total value (D
- GlobeNewswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; February 28, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,359 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,725 shares at DKK 815.50,163 shares at DKK 962.00,804 shares at DKK 1,025.00,93 shares at DKK 1,032.00,1,107
- GlobeNewswire
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; February 24, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in
